Clarity Pharmaceuticals and ImaginAb to collaborate on new cancer targets

On July 21, 2020 Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, and ImaginAb, Inc., a company that harnesses the specificity of monoclonal antibodies, reported that they have entered into a collaboration agreement to develop new targeted theranostic (diagnostic and therapy) products for a broad range of cancer types (Press release, ImaginAb, JUL 21, 2020, View Source;utm_medium=rss&utm_campaign=clarity-pharmaceuticals-and-imaginab-to-collaborate-on-new-cancer-targets [SID1234562118]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Clarity and ImaginAb will combine their proprietary technologies to develop novel minibody and cys-diabody radiopharmaceutical products using Clarity’s copper chelators to fully exploit the benefits of the theranostic pairing of copper-64 or copper-67.

ImaginAb’s CEO, Ian Wilson, said, "ImaginAb designs and engineers small, highly targeted proteins known as minibodies and cys-dibodies coupled with radioisotopes to image important molecular targets using standard Positron Emission Tomography (PET). We are excited to work together with Clarity on expanding the utility of ImaginAb’s technologies and entering the field of targeted radiotherapy."

Dr Alan Taylor, Clarity’s Executive Chairman, commented, "This collaboration will enable us to bring together ImaginAb’s unique expertise in designing minibodies, which are used to ensure rapid and highly specific targeting of tumours, with Clarity’s chelator technology, which will allow us to fully exploit the perfect pairing of copper-64 for diagnosis and copper-67 for therapy.

"The teams at Clarity and Imaginab are already working together to explore the synergies of combining their expertise in lead generation, manufacture, regulatory frameworks and clinical development to fast-track new theranostic products which will be the future of therapy. Combined, the companies will pursue their ultimate goal of developing better treatments for children and adults with cancer", Dr Taylor added.

Invitae to Announce Second Quarter 2020 Financial Results on August 4, 2020

On July 21, 2020 Invitae Corporation (NYSE: NVTA), a leading medical genetics company, reported that it will report its second quarter 2020 financial results on Tuesday, August 4, 2020 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights (Press release, Invitae, JUL 21, 2020, View Source [SID1234562178]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Invitae’s (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation)

To register for the conference call and webcast, please use one of the methods below. Upon registering, each participant will be provided with call details and a registrant ID. Reminders will also be sent to registered participants via email.

Online registration: View Source

Phone registration: (888) 869-1189 or (706) 643-5902

The live webcast of the call and slide deck may be accessed here or by visiting the investors section of the company’s website at ir.invitae.com. A replay of the webcast and conference call will be available shortly after the conclusion of the call and will be archived on the company’s website.

Following prepared remarks, management will respond to questions from analysts, subject to time limitations. We encourage our shareholders and those representing them to send in questions to ir.invitae.com.

Bergenbio Announces First Patient Dosed in Recurrent Glioblastoma Investigator Sponsored Phase I/II Study Assessing Selective AXL Inhibitor Bemcentinib

On July 20, 2020 BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, reported that the first patient has been dosed and continues on therapy in a trial assessing bemcentinib in recurrent glioblastoma (GBM) (Press release, BerGenBio, JUL 20, 2020, View Source [SID1234562076]). The trial is sponsored by Prof. Ichiro Nakano, MD, Professor in the Department of Neurosurgery and co-leader of the Neuro-Oncology Program at University of Alabama at Birmingham and funded by the National Cancer Institute (NCI).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This is an open label, multi-centre, intra-tumoral tissue pharmacokinetic (PK) study of bemcentinib in patients with recurrent glioblastoma for whom a surgical resection is medically indicated. The study will enrol up to 20 recurrent GBM patients, at up to 15 sites in the USA. 10 patients will be treated prior to surgery and 10 patients will have no pre-surgical treatment. However, all patients will receive treatment with bemcentinib following surgery. The endpoints of the study include an evaluation of bemcentinib’s ability to cross the blood brain barrier, AXL expression, pharmacokinetics, safety and tolerability, as well as efficacy assessments including Progression Free Survival and Overall Survival. More information about the trial can be found at View Source

Increased expression of the receptor tyrosine kinase AXL is significantly correlated with poor prognosis in GBM patients and preclinical data has suggested that bemcentinib may be a promising therapeutic agent for GBM, particularly in post-irradiation mesenchymal-transformed GBM tumors[1]. A comprehensive translational research programme will run in parallel with the clinical trial, this will be conducted by Prof. Jeff Supko, Harvard Medical School and Director of the Clinical Pharmacology Laboratory, Massachusetts General Hospital (Boston, USA).

Prof. Burt Nabors MD, the Chairman of the trial and Director of Neuro-Oncology at University of Alabama at Birmingham (UAB) and Director of UAB’s Centre for Clinical Translational Science’s Clinical Research Unit, commented: "GBM is among the most lethal of adult cancers. The median survival of patients remains less than two years despite the current available therapies, including surgery, radiation, and chemotherapy; development of more effective therapies is urgently needed. We welcome the opportunity to offer patients access to the investigational AXL inhibitor bemcentinib in this pilot study and look forward to initiating additional trial sites across the Adult Brain Tumour Consortium in the USA later this year."

Richard Godfrey, Chief Executive Officer of BerGenBio, commented: "We congratulate Prof. Nakano and Prof. Nabors on the start of this exciting clinical study, which we believe will provide us with important data regarding the ability of bemcentinib to cross the blood-brain barrier and potentially treat GBM patients. This clinical trial is based on pioneering preclinical research carried out by our collaborators, conducted at high profile research hospitals in the USA and is funded by National Cancer Institute (NCI). We look forward to reporting the potential of bemcentinib to improve patient outcomes in this very aggressive cancer."

Lantern Pharma Establishes Manufacturing Network in Preparation for Its Phase 2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer and a Phase 1 Clinical Trial for Solid Tumors and Glioblastoma

On July 20, 2020 Lantern Pharma (NASDAQ: LTRN), a clinical stage biotechnology company focused on leveraging artificial intelligence ("A.I."), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from its targeted oncology therapies, reported that entering into agreements with leading contract manufacturing companies for process development and manufacturing for two of Lantern’s oncology drug candidates, LP-300 and LP184 (Press release, Lantern Pharma, JUL 20, 2020, View Source [SID1234562120]). Lantern Pharma filed an 8-K on Thursday, July 16 describing a recent agreement for GMP manufacturing.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Lantern’s LP-300 is a small molecule drug candidate currently in preparation to enter phase 2 clinical trials in a growing, but unaddressed, type of non-small cell lung cancer (NSCLC) among never-smokers. Lantern is focused on developing LP-300 as a potential first-in-class combination therapy for never smoking (or non-smoking) NSCLC patients with histologically defined adenocarcinoma. NSCLC among never and non-smokers has a distinct molecular profile and according to the American Cancer Society, as many as 20% of people who die from lung cancer in the United States every year have never smoked or used any other form of tobacco. Leading researchers have started to classify lung cancer in never and non-smokers as having unique and distinct clinical, biological and pathological characteristics that have the potential to be impacted by new therapeutic options. According to market research, and data analytics firm, GlobalData, approximately $10 billion USD will be spent annually on NSCLC therapies in 2020 in the leading eight markets (by annual drug sales), with approximately $4 billion in the US.

Lantern’s LP-184 is a small molecule drug candidate currently in preclinical development for certain genomically defined solid tumors that overexpress certain RNA, as well as for glioblastoma multiforme (GBM). Lantern is currently planning to enter a Phase 1 clinical trial with this drug candidate in late 2021 or early 2022, after finalizing further biomarker studies with leading researchers, and after completing IND-enabling studies. Lantern estimates that, by 2025, potential annual sales for therapies in the genomically defined solid tumors targeted by LP-184 will be over $2.5 billion USD globally, and that potential annual sales for therapies to treat GBM will be nearly $1 billion globally. Both molecules have been advanced using Lantern’s proprietary RADR A.I. platform. With nearly 500 million data points, the RADR A.I. platform uses machine learning techniques, genomics, and computational biology methods to accelerate drug development by accelerating the discovery of potential mechanisms of action and developing genomic and biomarker signatures that correlate to drug UNDER EMBARGO UNTIL 8:00 AM EASTERN MONDAY, 07/20/20 response in cancer patients.

Both molecules, LP-300 and LP-184, are being developed with the vision of pairing them with companion diagnostics generated, in-part by RADR, to enable precision medicine trials and selection of patients with the highest probability of benefiting from the drug and offering the potential for best-in-class outcomes.

Panna Sharma, CEO and President of Lantern Pharma, stated, "the launch of manufacturing activities with our partners represents key steps in establishing a specialized global manufacturing network that can provide Lantern with critical scalability, flexibility and innovation to help maximize the impact of our capital resources and efficiently prepare our drug supply for our clinical trials and studies." Sharma continued, "These key capabilities are especially important now as we advance LP-300 and LP-184 towards commencement of clinical trials that can likely shape the timing and terms of potential future partnering discussions."

INmune Bio, Inc. Announces Closing of $25 Million Public Offering of Common Stock Including Full Exercise of Underwriters’ Over-Allotment Option

On July 20, 2020 INmune Bio, Inc. (NASDAQ: INMB) (the "Company" or "INmune"), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, reported the closing of its previously announced underwritten public offering of an aggregate of 2,173,914 shares of its common stock at a public offering price of $10.00 per share and the exercise in full of the underwriters’ option to purchase an additional 326,086 shares of common stock (Press release, INmune Bio, JUL 20, 2020, View Source [SID1234562121]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A total of 2,500,000 shares of common stock were issued in the offering, including the full exercise of the over-allotment option.

The gross proceeds to INmune from this offering are approximately $23.1 million, before deducting underwriting discounts and commissions and other offering expenses payable by INmune. INmune intends to use the net proceeds from the offering for general corporate purposes, including to support research and development, including clinical trials.

BTIG, LLC acted as sole book-running manager of the offering, and National Securities Corporation acted as a co-manager.

The offering was made pursuant to the shelf registration statement on Form S-3 (File No. 333-237368) that was filed with the Securities and Exchange Commission (the "SEC") on March 24, 2020 and became effective on April 2, 2020, including the related base shelf prospectus, as supplemented by the prospectus supplement dated July 16, 2020. The final prospectus supplement and accompanying base shelf prospectus are available on the SEC’s website at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.